SEOUL, South Korea--(BUSINESS WIRE)--GeneMedicine Co., Ltd., a leader in the field of oncolytic adenovirus platform for the treatment of intractable cancers, announced today that the company has appointed Robert S. Langer, Sc.D., the David H. Koch Institute Professor at MIT to its Scientific Advisory Board.
Dr. Langer is a world-renowned scientist and entrepreneur and is widely regarded for his decades of accomplishments and contributions to medicine and biotechnology. His pioneering work in the field of drug delivery systems has been widely recognized. Dr. Langer has authored more than 1,500 scientific papers and has over 1,350 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 400 pharmaceutical, chemical, biotechnology, and medical device companies.
Dr. Langer has received over 220 awards and honors, including the 2006 United States National Medal of Science, the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, and the 2008 Millennium Prize, the world’s prestigious technology prize. In addition, Dr. Langer is the youngest person in history at age 43 to be elected to all three American science academies: the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.
Dr. Langer’s accomplishments have been recognized in media as well. Dr. Langer has been named one of the 25 most important individuals in biotechnology in the world by Forbes magazine (1999) and Bio World (1990), one of the 20 most important people in biotechnology by Discover magazine (2002), and one of the 15 innovators who will reinvent our future by Forbes (2002).
Dr. Langer served as a member of the US FDA’s Science Board, the FDA’s highest advisory board, from 1995 to 2002 and as its Chairman from 1999 to 2002.
Dr. Langer received his Bachelor’s Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of Technology in 1974, both in chemical engineering. He has received numerous honorary doctorates from prestigious academic institutions worldwide, including Harvard University and Yale University.
″We are honored and excited to welcome Dr. Langer to our Scientific Advisory Board at this important time of GeneMedicine’s development to become a leading biopharmaceutical company,” stated Chae-Ok Yun, Ph.D., CEO of GeneMedicine. ″Dr. Langer’s extensive experience and expertise in helping biotechnology companies from the research stage through commercialization will be invaluable as GeneMedicine establishes leadership in oncolytic adenovirus platform.”
″I am pleased to become a scientific and strategy advisor of GeneMedicine,” said Dr. Langer. ″I believe that GeneMedicine is poised to make a substantial contribution and impact in the fields of oncolytic virus treatment for cancer. I look forward to helping the company to continue to advance its mission of perfecting its oncolytic virus platform for cancer treatment and commercialization of its technologies,” added Dr. Langer.
About GeneMedicine Co., Ltd.
GeneMedicine Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing its oncolytic adenovirus platform for the treatment of intractable cancers. GeneMedicine’s research programs utilize novel and innovative adenoviral vector platforms, which can selectively lyse cancer cells, express numerous combinations of therapeutic transgenes at a high level, induce a robust antitumor immune response, and deliver systemically. The company’s current pipelines include treatments based on oncolytic adenovirus against solid tumors (GM 101), pancreatic cancers (GM 102), and metastatic lung and liver cancers (GM 103). GeneMedicine is committed to surpassing limitations, exceeding expectations in the field of oncolytic virotherapy and gene and cell therapy.